Non-alcoholic fatty liver disease/non-alcoholic steatohepatitis (NAFLD/NASH): diagnosis and clinical course

被引:52
|
作者
Cortez-Pinto, H
Camilo, ME
机构
[1] Univ Lisbon, Fac Med, Univ Hosp Santa Maria, Dept Gastroenterol, P-1649035 Lisbon, Portugal
[2] Hosp Santa Maria, Inst Mol Med, Ctr Nutr & Metab, Ctr Gastroenterol, P-1649035 Lisbon, Portugal
关键词
non-alcoholic steatohepatitis; non-alcoholic fatty liver disease; diagnosis; clinical course; insulin resistance; diabetes; obesity;
D O I
10.1016/j.bpg.2004.06.021
中图分类号
R57 [消化系及腹部疾病];
学科分类号
摘要
Non-alcoholic fatty liver disease (NAFLD) is a frequent syndrome encompassing fatty liver alone and steatohepatitis (NASH). Often asymptomatic, the suspicion arises because of abnormal aminotransferases or a bright liver on abdominal ultrasound. It should be suspected during evaluation of associated conditions as obesity, diabetes or dyslipidaemia. The diagnostic evaluation must exclude other potential causes of liver disease and may include a liver biopsy, the only method able to confirm features of necroinflammation and fibrosis that define NASH and its prognostic implications. Indeed, the presence of necroinflammation has been associated with a significant risk of progression to cirrhosis and eventually hepatocellular carcinoma. Age >45 years, obesity and diabetes have also been associated with an increased risk of liver fibrosis and progression to cirrhosis. Given the high prevalence of NAFLD, general measures of life-style changes, focusing on exercise, diet, and total alcohol abstinence, should be implemented before a liver biopsy is considered.
引用
收藏
页码:1089 / 1104
页数:16
相关论文
共 50 条
  • [1] Non-alcoholic fatty liver disease (NAFLD). Non-alcoholic steatohepatitis - NASH
    Keller, KM
    [J]. MONATSSCHRIFT KINDERHEILKUNDE, 2004, 152 (08) : 864 - 869
  • [2] Non-alcoholic fatty liver disease/non-alcoholic steatohepatitis (NAFLD/NASH): treatment
    Bugianesi, E
    Marzocchi, R
    Villanova, N
    Marchesini, G
    [J]. BEST PRACTICE & RESEARCH CLINICAL GASTROENTEROLOGY, 2004, 18 (06) : 1105 - 1116
  • [3] Non-Alcoholic Fatty Liver Disease (NAFLD) and Non-Alcoholic Steatohepatitis (NASH) in HIV
    Jürgen Kurt Rockstroh
    [J]. Current HIV/AIDS Reports, 2017, 14 : 47 - 53
  • [4] Non-Alcoholic Fatty Liver Disease (NAFLD) and Non-Alcoholic Steatohepatitis (NASH) in HIV
    Rockstroh, Juergen Kurt
    [J]. CURRENT HIV/AIDS REPORTS, 2017, 14 (02) : 47 - 53
  • [6] Clinical impact of sexual dimorphism in non-alcoholic fatty liver disease (NAFLD) and non-alcoholic steatohepatitis (NASH)
    Burra, Patrizia
    Bizzaro, Debora
    Gonta, Anna
    Shalaby, Sarah
    Gambato, Martina
    Morelli, Maria Cristina
    Trapani, Silvia
    Floreani, Annarosa
    Marra, Fabio
    Brunetto, Maurizia Rossana
    Taliani, Gloria
    Villa, Erica
    [J]. LIVER INTERNATIONAL, 2021, 41 (08) : 1713 - 1733
  • [7] Non-alcoholic Fatty Liver Disease (NAFLD) and non-alcoholic Steatohepatitis (NASH): Pathophysiology and Nutritional Aspects
    Schattenberg, Joern M.
    [J]. ERNAHRUNGS UMSCHAU, 2015, 62 (02): : M92 - M100
  • [8] Linagliptin is an Effective Therapeutic for Non-alcoholic Fatty Liver Disease (NAFLD) and Non-alcoholic Steatohepatitis (NASH)
    Klein, Thomas
    Mark, Michael
    [J]. DIABETES, 2012, 61 : A265 - A266
  • [9] Noninvasive assessment of fibrosis in non-alcoholic fatty liver disease (NAFLD) and non-alcoholic steatohepatitis (NASH)
    Miele, Luca
    Forgione, Alessandra
    Gasbarrini, Giovanni
    Grieco, Antonio
    [J]. TRANSLATIONAL RESEARCH, 2007, 149 (03) : 114 - 125
  • [10] Recurrence of Non-Alcoholic Fatty Liver Disease (NAFLD) and Non-Alcoholic Steatohepatitis (NASH) Following Liver Transplantation for NASH Cirrhosis
    Matsuoka, Lea
    Slaughter, James
    Campbell, Kathyrn
    Kerr, Ashlie
    Hamel, Stephanie
    Garza, Carissa
    Chotai, Pranit
    Alexopoulos, Sophoclis
    Scanga, Andrew
    [J]. AMERICAN JOURNAL OF TRANSPLANTATION, 2021, 21 : 15 - 15